Literature DB >> 19888515

Heparin, heparan sulfate and heparanase in inflammatory reactions.

Jin-Ping Li1, Israel Vlodavsky.   

Abstract

Heparan sulfate (HS) proteoglycans at the cell surface and in the extracellular matrix of most animal tissues are essential in development and homeostasis, and are implicated in disease processes. Emerging evidence demonstrates the important roles of HS in inflammatory reactions, particularly in the regulation of leukocyte extravasation. Heparin, a classical anticoagulant, exhibits anti-inflammatory effects in animal models and in the clinic, presumably through interference with the functions of HS, as both polysaccharides share a high similarity in molecular structure. Apart of regulation during biosynthesis, the structures of HS and heparin are significantly modulated by heparanase, an endoglycosidase that is upregulated in a number of inflammatory conditions. Exploring the physiological roles of HS and heparin and the mode of heparanase action in modulating their functions during inflammation responses is of importance for future studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19888515     DOI: 10.1160/TH09-02-0091

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  72 in total

1.  SPECT imaging of peripheral amyloid in mice by targeting hyper-sulfated heparan sulfate proteoglycans with specific scFv antibodies.

Authors:  Jonathan S Wall; Tina Richey; Alan Stuckey; Robert Donnell; Arie Oosterhof; Toin H van Kuppevelt; Nicole C Smits; Stephen J Kennel
Journal:  Nucl Med Biol       Date:  2011-09-29       Impact factor: 2.408

2.  Heparin impairs angiogenic signaling and compensatory lung growth after left pneumonectomy.

Authors:  Duy T Dao; Lorenzo Anez-Bustillos; Jared Ourieff; Amy Pan; Paul D Mitchell; Hiroko Kishikawa; Gillian L Fell; Meredith A Baker; Randolph S Watnick; Hong Chen; Thomas E Hamilton; Michael S Rogers; Diane R Bielenberg; Mark Puder
Journal:  Angiogenesis       Date:  2018-06-28       Impact factor: 9.596

3.  An approach for separation and complete structural sequencing of heparin/heparan sulfate-like oligosaccharides.

Authors:  Rongrong Huang; Jian Liu; Joshua S Sharp
Journal:  Anal Chem       Date:  2013-05-28       Impact factor: 6.986

4.  Method development and analysis of free HS and HS in proteoglycans from pre- and postmenopausal women: evidence for biosynthetic pathway changes in sulfotransferase and sulfatase enzymes.

Authors:  Wei Wei; Rebecca L Miller; Julie A Leary
Journal:  Anal Chem       Date:  2013-05-28       Impact factor: 6.986

5.  Involvement of Heparanase in Empyema: Implication for Novel Therapeutic Approaches.

Authors:  Moshe Lapidot; Uri Barash; Yaniv Zohar; Yuval Geffen; Inna Naroditsky; Neta Ilan; Lael Anson Best; Israel Vlodavsky
Journal:  J Clin Cell Immunol       Date:  2015-02

6.  The potential of heparanase as a therapeutic target in cancer.

Authors:  Claudio Pisano; Israel Vlodavsky; Neta Ilan; Franco Zunino
Journal:  Biochem Pharmacol       Date:  2014-02-22       Impact factor: 5.858

7.  Blood management-issues: the panic of coagulopathic bleeding--is there a rational approach?

Authors:  Bruce D Spiess
Journal:  J Extra Corpor Technol       Date:  2011-03

Review 8.  Versatile role of heparanase in inflammation.

Authors:  Rachel Goldberg; Amichay Meirovitz; Nir Hirshoren; Raanan Bulvik; Adi Binder; Ariel M Rubinstein; Michael Elkin
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

Review 9.  Involvement of heparanase in atherosclerosis and other vessel wall pathologies.

Authors:  Israel Vlodavsky; Miry Blich; Jin-Ping Li; Ralph D Sanderson; Neta Ilan
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

10.  Characterizing the microstructure of heparin and heparan sulfate using N-sulfoglucosamine 1H and 15N NMR chemical shift analysis.

Authors:  Derek J Langeslay; Consuelo N Beecher; Annamaria Naggi; Marco Guerrini; Giangiacomo Torri; Cynthia K Larive
Journal:  Anal Chem       Date:  2012-12-31       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.